Humanwell Healthcare (Group) Co Ltd (600079):製薬・医療:M&Aディール及び事業提携情報

◆英語タイトル:Humanwell Healthcare (Group) Co Ltd (600079) - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード:DATA904C7991
◆発行会社(調査会社):GlobalData
◆発行日:2018年10月
◆ページ数:42
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:中国
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD250 ⇒換算¥37,000見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD500 ⇒換算¥74,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD750 ⇒換算¥111,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要はこちらでご確認いただけます。



【レポートの概要】

Summary
Humanwell Healthcare (Group) Co Ltd (Humanwell), formerly Wuhan Humanwell Hi-Tech Industry Co Ltd is a pharmaceutical company that offers generic products. The company offers pharmaceutical, medical instrument and reproductive health care products and technologies. Its products include anesthetics, biological products, herbal medicines, CNS medicines, women’s health, anti-infection drugs, medical devices, OTC medicines and other products. Humanwell also provides buflomedil hydrochloride injectable, pantoprazole sodium injectable, omeprazole sodium injectable, phloroglucinol injectable, and simvastatin capsules. The company produces products in the forms of injection, tablets, syrup, granules, capsules, and suspension. It has partnership with other research institutes for investments, commercial distribution and research and development. Humanwell is headquartered in Wuhan, China.

Humanwell Healthcare (Group) Co Ltd (600079) – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 4
List of Figures 4
Humanwell Healthcare (Group) Co Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Humanwell Healthcare (Group) Co Ltd, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6
Humanwell Healthcare (Group) Co Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Humanwell Healthcare (Group) Co Ltd, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8
Humanwell Healthcare (Group) Co Ltd, Medical Devices Deals, 2012 to YTD 2018 10
Humanwell Healthcare (Group) Co Ltd, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 11
Humanwell Healthcare (Group) Co Ltd, Pharmaceuticals & Healthcare, Deal Details 13
Venture Financing 13
Ambrx Raises USD45 Million in Venture Financing 13
Private Equity 15
AGIC Capital Acquires Ritedose From Olympus Partners 15
Licensing Agreements 17
Elite Pharma Enters into Licensing Agreement with Epic Pharma for Abuse-Deterrent ELI-200 17
Elite Pharma Enters Into Licensing Agreement With Epic Pharma For Twelve Generic Products 18
Equity Offering 19
Humanwell Healthcare Decreases Size of Private Placement of Shares for USD174 Million 19
Wuhan Humanwell Healthcare Plans Private Placement of Shares for up to USD412.5 Million 20
Wuhan Humanwell Hi-tech Industry Plans For Private Placement Of Shares For Up To US$163 Million 21
Debt Offering 22
Humanwell Healthcare to Raise USD302 Million in Private Placement of Notes 22
Humanwell Healthcare Raises USD150.8 Million in First Tranche of 4.99% Public Offering of Notes Due 2018 23
Humanwell Healthcare to Raise USD296.81 Million in Commercial Paper Offering 24
Humanwell Healthcare Raises USD224 Million in Public Offering of Notes 25
Humanwell Healthcare Plans to Raise USD309 Million in Public Offering of Notes 26
Humanwell Healthcare to Raise up to USD155 Million in Public Offering of Bonds 27
Wuhan Humanwell Announces Public Offering Of Notes Due 2015 For US$95 MIllion 28
Acquisition 29
CSL to Acquire Remaining 20% Stake in Wuhan Zhong Yuan Rui De Biological Products from Humanwell Healthcare Group for USD102 Million 29
Humanwell Healthcare Sells Bio-Pharma Unit for USD53 Million 30
CSL Acquires 80% Equity Stake in Wuhan Zhong Yuan Rui De Biological Products from Humanwell Healthcare Group for USD352 Million 31
Humanwell Healthcare and PuraCap Pharma Acquire 100% Stake in Epic Pharma 32
Humanwell Healthcare Acquires Epic RE Holdco for USD21 Million 34
Humanwell Healthcare Plans to Acquire 70% Stake in Chengdu Kanghong Pharma for USD53 Million 35
Humanwell Healthcare Plans to Sell Shenzhen Biotech Firm for USD36 Million 36
Humanwell Healthcare to Acquire Yichang Sanxia Pharmaceutical for USD71.06 Million 37
Humanwell Healthcare Plans to Acquire 70% Stake in Pharmaceutical Firm for USD40 Million 38
Humanwell Healthcare (Group) Co Ltd – Key Competitors 39
Humanwell Healthcare (Group) Co Ltd – Key Employees 40
Humanwell Healthcare (Group) Co Ltd – Locations And Subsidiaries 41
Head Office 41
Other Locations & Subsidiaries 41
Appendix 42
Methodology 42
About GlobalData 42
Contact Us 42
Disclaimer 42

List of Tables
Humanwell Healthcare (Group) Co Ltd, Pharmaceuticals & Healthcare, Key Facts, 2017 2
Humanwell Healthcare (Group) Co Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Humanwell Healthcare (Group) Co Ltd, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6
Humanwell Healthcare (Group) Co Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Humanwell Healthcare (Group) Co Ltd, Deals By Therapy Area, 2012 to YTD 2018 8
Humanwell Healthcare (Group) Co Ltd, Medical Devices Deals, 2012 to YTD 2018 10
Humanwell Healthcare (Group) Co Ltd, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 11
Ambrx Raises USD45 Million in Venture Financing 13
AGIC Capital Acquires Ritedose From Olympus Partners 15
Elite Pharma Enters into Licensing Agreement with Epic Pharma for Abuse-Deterrent ELI-200 17
Elite Pharma Enters Into Licensing Agreement With Epic Pharma For Twelve Generic Products 18
Humanwell Healthcare Decreases Size of Private Placement of Shares for USD174 Million 19
Wuhan Humanwell Healthcare Plans Private Placement of Shares for up to USD412.5 Million 20
Wuhan Humanwell Hi-tech Industry Plans For Private Placement Of Shares For Up To US$163 Million 21
Humanwell Healthcare to Raise USD302 Million in Private Placement of Notes 22
Humanwell Healthcare Raises USD150.8 Million in First Tranche of 4.99% Public Offering of Notes Due 2018 23
Humanwell Healthcare to Raise USD296.81 Million in Commercial Paper Offering 24
Humanwell Healthcare Raises USD224 Million in Public Offering of Notes 25
Humanwell Healthcare Plans to Raise USD309 Million in Public Offering of Notes 26
Humanwell Healthcare to Raise up to USD155 Million in Public Offering of Bonds 27
Wuhan Humanwell Announces Public Offering Of Notes Due 2015 For US$95 MIllion 28
CSL to Acquire Remaining 20% Stake in Wuhan Zhong Yuan Rui De Biological Products from Humanwell Healthcare Group for USD102 Million 29
Humanwell Healthcare Sells Bio-Pharma Unit for USD53 Million 30
CSL Acquires 80% Equity Stake in Wuhan Zhong Yuan Rui De Biological Products from Humanwell Healthcare Group for USD352 Million 31
Humanwell Healthcare and PuraCap Pharma Acquire 100% Stake in Epic Pharma 32
Humanwell Healthcare Acquires Epic RE Holdco for USD21 Million 34
Humanwell Healthcare Plans to Acquire 70% Stake in Chengdu Kanghong Pharma for USD53 Million 35
Humanwell Healthcare Plans to Sell Shenzhen Biotech Firm for USD36 Million 36
Humanwell Healthcare to Acquire Yichang Sanxia Pharmaceutical for USD71.06 Million 37
Humanwell Healthcare Plans to Acquire 70% Stake in Pharmaceutical Firm for USD40 Million 38
Humanwell Healthcare (Group) Co Ltd, Key Competitors 39
Humanwell Healthcare (Group) Co Ltd, Key Employees 40
Humanwell Healthcare (Group) Co Ltd, Subsidiaries 41

List of Figures
Humanwell Healthcare (Group) Co Ltd, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
Humanwell Healthcare (Group) Co Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
Humanwell Healthcare (Group) Co Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
Humanwell Healthcare (Group) Co Ltd, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
Humanwell Healthcare (Group) Co Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Humanwell Healthcare (Group) Co Ltd, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 6
Humanwell Healthcare (Group) Co Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Humanwell Healthcare (Group) Co Ltd, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8
Humanwell Healthcare (Group) Co Ltd, Medical Devices Deals, 2012 to YTD 2018 10

★海外企業調査レポート[Humanwell Healthcare (Group) Co Ltd (600079):製薬・医療:M&Aディール及び事業提携情報]についてメールでお問い合わせはこちら

■おすすめ企業レポート■
  • Berli Jucker Public Co Ltd:企業の戦略・SWOT・財務情報
    Berli Jucker Public Co Ltd - Strategy, SWOT and Corporate Finance Report Summary Berli Jucker Public Co Ltd - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and servi …
  • ethris GmbH:製薬・医療:M&Aディール及び事業提携情報
    Summary Ethris GmbH (Ethris) is a biotech company that develops RNA-based therapies. The company develops therapeutics based on its proprietary platform technologies. It uses technologies including magnetovax and SNIM RNA. Ethris’ magnetovax is a platform for personalized tumor vaccines localized an …
  • The Israel Electric Corporation Ltd:電力:M&Aディール及び事業提携情報
    Summary The Israel Electric Corporation Ltd (IECL) formerly Palestine Electric Corporation Ltd., is an integrated electric utility that carries out the generation, transmission, distribution, sale and supply of electricity. The State of Israel owns around 99.85% of the company. It generates power ma …
  • Osiris Therapeutics Inc (OSIR):企業の財務・戦略的SWOT分析
    Osiris Therapeutics Inc (OSIR) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weakn …
  • Zen Technologies Limited
    Zen Technologies Limited - Strategy, SWOT and Corporate Finance Report Summary Zen Technologies Limited - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service o …
  • De La Rue Plc:企業の戦略・SWOT・財務分析
    De La Rue Plc - Strategy, SWOT and Corporate Finance Report Summary De La Rue Plc - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate …
  • Gem Pharmaceuticals LLC-製薬・医療分野:企業M&A・提携分析
    Summary Gem Pharmaceuticals LLC (Gem Pharmaceuticals) is a clinical-stage biopharmaceutical company that develops proprietary anthracycline derivatives. The company’s pipeline products include GPX-150 for oncology, topical GPX-150 for inflammation, GPX 150 oral formulations and potency analogues pro …
  • Doutor Coffee Co. Ltd.:企業の戦略・SWOT・財務分析
    Doutor Coffee Co. Ltd. - Strategy, SWOT and Corporate Finance Report Summary Doutor Coffee Co. Ltd. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offer …
  • U.S. Venture Inc:企業の戦略的SWOT分析
    U.S. Venture Inc - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and servi …
  • FluGen Inc-製薬・医療分野:企業M&A・提携分析
    Summary FluGen Inc (FluGen) is a healthcare services provider that offers vaccine and therapies. The company discovers, develops and commercializes new methods for the prevention and treatment of influenza infections. Its product includes redeeflu that contains mutations in the M2 gene of the virus. …
  • Abcam Plc (ABC):製薬・医療:M&Aディール及び事業提携情報
    Summary Abcam Plc (Abcam) is a supplier of life science research tools for analysis of living cells at molecular level to understand a wide range of disease conditions. The company develops and markets antibodies and other related products. Its product portfolio includes primary antibodies, secondar …
  • Weatherford International Plc (WFT):石油・ガス:M&Aディール及び事業提携情報
    Summary Weatherford International Plc (Weatherford) is an oilfield service provider. The company offers equipment and services utilized in the drilling, evaluation, completion, production and intervention of oil and natural gas wells. Its product line includes artificial lift systems, completion sys …
  • Meredith Corporation:企業の戦略・SWOT・財務情報
    Meredith Corporation - Strategy, SWOT and Corporate Finance Report Summary Meredith Corporation - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings …
  • Jaiprakash Power Ventures Ltd (JPPOWER):電力:M&Aディール及び事業提携情報
    Summary Jaiprakash Power Ventures Ltd (Jaiprakash Power) is a power utility. It plans, develops, implements, and operates electric projects. The company produces electricity using hydro and coal sources. Jaiprakash Power also has development interests in the Hirong hydroelectric project and the Lowe …
  • Maersk Drilling AS:石油・ガス:M&Aディール及び事業提携情報
    Summary Maersk Drilling A/S (Maersk) formerly Maersk Contractors, a subsidiary of A.P. Moller - Maersk A/S, is an oil and gas company that offers drilling services. The company operates a fleet of drilling barges such as smaller rigs optimized for shallow water drilling and operated on management co …
  • Symphony Ltd:企業の戦略・SWOT・財務分析
    Symphony Ltd - Strategy, SWOT and Corporate Finance Report Summary Symphony Ltd - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate a …
  • Henry Ford Health System:企業の戦略的SWOT分析
    Henry Ford Health System - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products a …
  • Fluxys SA:石油・ガス:M&Aディール及び事業提携情報
    Summary Fluxys SA (Fluxys), a subsidiary of Publigas, is an independent natural gas infrastructure group. It carries out natural gas transmission, gas storage and terminalling of liquefied natural gas (LNG). Besides, the group conducts natural gas trading activities in the spot market. The company s …
  • Mercury General Corporation:戦略・SWOT・企業財務分析
    Mercury General Corporation - Strategy, SWOT and Corporate Finance Report Summary Mercury General Corporation - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and ser …
  • Husky Energy Inc Oil & Gas Exploration and Production Operations and Cost Analysis – Q4, 2017
    Husky Energy Inc Oil & Gas Exploration and Production Operations and Cost Analysis - Q4, 2017 Summary Husky Energy Inc (Husky) is an integrated energy company. It operates across the oil and gas value chain. Its upstream operations include the exploration, development and production of crude oil, bi …

◆H&Iグローバルリサーチ株式会社のお客様(例)◆